Format

Send to

Choose Destination
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Collaborators (571)

Collins S, Pearce G, Storfer S, Rhode R, Worm SW, Sabin CA, Friis-Møller N, Tverland J, Kamara A, Sjøl S, Lundgren JD, Sawitz A, Brandt RS, Rickenbach M, Fanti L, Krum E, Gras L, Geffard S, Sundström A, Delforge M, Fontas E, Torres F, McManus H, Wright S, Kjaer J, de Wolf F, Zaheri S, Gras L, Bronsveld W, Hillebrand-Haverkort ME, Prins JM, Bos JC, Eeftinck Schattenkerk JK, Geerlings SE, Godfried MH, Lange JM, van Leth FC, Lowe SH, van der Meer JT, Nellen FJ, Pogány K, van der Poll T, Reiss P, Ruys TA, Sankatsing, Steingrover R, van Twillert G, van der Valk M, van Vonderen MG, Vrouenraets SM, van Vugt M, Wit FW, van Eeden A, ten Veen JH, van Dam PS, Roos JC, Brinkman K, Frissen PH, Weigel HM, Mulder JW, van Gorp EC, Meenhorst PL, Mairuhu AT, Veenstra J, Danner SA, Van Agtmael MA, Claessen FA, Perenboom RM, Rijkeboer A, van Vonderen M, Richter C, van der Berg J, van Leusen R, Vriesendorp R, Jeurissen FJ, Kauffmann RH, Koger EL, Bravenboer B, ten Napel CH, Kootstra GJ, Sprenger HG, Miesen WM, Doedens R, Scholvinck EH, ten Kate RW, van Houte DP, Polee M, Kroon FP, van den Broek, van Dissel JT, Schippers EF, Schreij G, van de Geest S, Verbon A, Koopmans PP, Keuter M, Post F, van der Ven AJ, van der Ende ME, Gyssens IC, van der Feltz M, den Hollander JG, de Marie S, Nouwen JL, Rijnders BJ, de Vries TE, Juttmann JR, van de Heul C, van Kasteren ME, Elisabeth S, Schneider MM, Bonten MJ, Borleffs JC, Ellerbroek PM, Hoepelman IM, Jaspers CA, Schouten I, Schurink CA, Blok WL, Tanis AA, Groeneveld PH, Salamon R, Beylot J, Le Bras M, Dupon M, Pellegrin JL, Ragnaud JM, Dabis F, Chêne G, Thiébaut R, Lawson-Ayayi S, Blaizeau MJ, Decoin M, Delveaux S, Hannapier C, d'Ivernois C, Leleux O, Uwamaliya-Nziyumvira B, Palmer G, Touchard D, Jacqmin-Gadda H, Lavignolle V, Balestre E, Decoin M, Formaggio AM, Labarerre S, Vimard E, Dutoit D, Pereira F, Boulant B, Bonnal F, Farbos S, Bonarek M, Bonnet F, Bernard N, Caubet O, Cazanave C, Dauchy FA, De La Taille C, Dupon M, Duffau P, Dutronc H, Greib C, Lacoste D, Lafarie S, Lazaro E, Malvy D, Mercié P, Morlat P, Neau D, Ochoa A, Pellegrin JL, Pillot-Debelleix M, Pistone T, Ragnaud JM, Receveur MC, Vandenhende MA, Viallard JF, Blanco P, Moreau JF, Fleury H, Lafon ME, Masquelier B, Pellegrin I, Breilh D, Miremont-Salamé G, Caunègre L, Gerard Y, Loste P, Ceccaldi J, Tchamgoué S, De Witte S, Law M, Petoumenos K, McManus H, Wright S, Moore R, Edwards S, Hoy J, Watson K, Roth N, Nicholson J, Bloch M, Franic T, Baker D, McFarlane R, Carr A, Cooper D, Chuah J, Fankhauser W, Nolan D, Mallal S, Forsdyke C, Calvo G, Torres F, Mateu S, Domingo P, Sambeat MA, Gatell J, Del Cacho E, Cadafalch J, Fuster M, Codina C, Sirera G, Vaqué A, Clumeck N, De Wit S, Gerard M, Kabeya K, Konopnicki D, Libois A, Payen MC, Poll B, Van Laethem Y, Neaton J, Bartsch G, El-Sadr WM, Krum E, Thompson G, Wentworth D, Luskin-Hawk R, Telzak E, El-Sadr WM, Abrams DI, Cohn D, Markowitz N, Mushatt D, Friedland G, Perez G, Tedaldi E, Fisher E, Gordin F, Crane LR, Sampson J, Baxter J, Kirk O, Mocroft A, Ellefson M, Phillips AN, Lundgren JD, Losso M, Elias C, Vetter N, Zangerle R, Karpov I, Vassilenko A, Mitsura VM, Suetnov O, Clumeck N, De Wit S, Poll B, Colebunders R, Vandekerckhove L, Hadziosmanovic V, Kostov K, Begovac I, Machala L, Rozsypal H, Sedlacek D, Nielsen J, Kronborg G, Benfield T, Larsen M, Gerstoft J, Katzenstein T, Hansen AB, Skinhøj P, Pedersen C, Oestergaard L, Zilmer K, Smidt J, Ristola M, Katlama C, Viard JP, Girard PM, Livrozet JM, Vanhems P, Pradier C, Dabis F, Neau D, Rockstroh J, Schmidt R, van Lunzen J, Degen O, Stellbrink HJ, Staszewski S, Bogner J, Fätkenheuer G, Kosmidis J, Gargalianos P, Xylomenos G, Perdios J, Panos G, Filandras A, Karabatsaki E, Sambatakou H, Banhegyi D, Mulcahy F, Yust I, Turner D, Burke M, Pollack S, Hassoun G, Maayan S, Chiesi A, Esposito R, Mazeu I, Mussini C, Arici C, Pristera R, Mazzotta F, Gabbuti A, Vullo V, Lichtner M, Chirianni A, Montesarchio E, Gargiulo M, Antonucci G, Iacomi F, Narciso P, Vlassi C, Zaccarelli M, Lazzarin A, Finazzi R, Galli M, Ridolfo A, d'Arminio Monforte A, Rozentale B, Aldins P, Chaplinskas S, Hemmer R, Staub T, Reiss P, Bruun J, Maeland A, Ormaasen V, Knysz B, Gasiorowski J, Horban A, Bakowska E, Prokopowicz D, Flisiak R, Boron-Kaczmarska A, Pynka M, Beniowski M, Mularska E, Trocha H, Jablonowska E, Malolepsza E, Wojcik K, Antunes F, Valadas E, Mansinho K, Maltez F, Duiculescu D, Rakhmanova A, Vinogradova E, Buzunova S, Jevtovic D, Mokrás M, Staneková D, Tomazic J, González-Lahoz J, Soriano V, Martin-Carbonero L, Labarga P, Moreno S, Clotet B, Jou A, Paredes R, Tural C, Puig J, Bravo I, Gatell JM, Miró JM, Domingo P, Gutierrez M, Mateo G, Sambeat MA, Karlsson A, Persson PO, Flamholc L, Ledergerber B, Weber R, Francioli, Cavassini M, Hirschel B, Boffi E, Furrer H, Battegay M, Elzi L, Kravchenko E, Chentsova N, Kutsyna G, Servitskiy S, Antoniak S, Krasnov M, Barton S, Johnson AM, Mercey D, Phillips A, Johnson MA, Mocroft A, Murphy M, Weber J, Scullard G, Fisher M, Leen C, Morfeldt L, Thulin G, Sundström A, Akerlund B, Koppel K, Karlsson A, Flamholc L, Håkangård C, Moroni M, Antinori A, Carosi G, Cauda R, Chiodo F, Di Perri G, Galli M, Ghinelli F, Iardino R, Ippolito G, Lazzarin A, Mazzotta F, Panebianco R, Pastore G, Perno CF, d'Arminio Monforte A, Pezzotti P, Montroni M, Scalise G, Costantini A, Riva A, Tirelli U, Martellotta F, Pastore G, Ladisa N, Suter F, Maggiolo F, Chiodo F, Colangeli V, Fiorini C, Carosi G, Cristini G, Torti C, Minardi C, Bertelli D, Quirino T, Manconi PE, Piano P, Pizzigallo E, D'Alessandro M, Carnevale G, Zoncada A, Ghinelli F, Sighinolfi L, Leoncini F, Mazzotta F, Pozzi M, Lo Caputo S, Grisorio B, Ferrara S, Pagano G, Cassola G, Alessandrini A, Piscopo R, Soscia F, Tacconi L, Orani A, Perini P, Tommasi D, Congedo P, Chiodera F, Castelli P, Moroni M, Lazzarin A, Rizzardini G, Caggese L, d'Arminio Monforte A, Galli A, Merli S, Pastecchia C, Moioli MC, Esposito R, Mussini C, Gori A, Cagni S, Abrescia N, Chirianni A, Izzo CM, De Marco M, Viglietti R, Manzillo E, Ferrari C, Pizzaferri P, Filice G, Bruno R, Magnani G, Ursitti MA, Arlotti M, Ortolani P, Cauda R, Andreoni M, Antinori A, Antonucci G, Narciso P, Tozzi V, Vullo V, De Luca A, Zaccarelli M, Acinapura R, De Longis P, Trotta MP, Lichtner M, Carletti F, Mura MS, Mannazzu M, Caramello P, Di Perri G, Orofino GC, Sciandra M, Raise E, Ebo F, Pellizzer G, Buonfrate D, Pradier C, Fontas E, Caissotti C, Dellamonica P, Bentz L, Bernard E, De Salvador-Guillouet F, Durant J, Mondain-Miton V, Perbost I, Prouvost-Keller B, Pugliese P, Rahelinirina V, Roger PM, Cua E, Farhad R, Ferrando S, Vassallo M, Baëz E, Battegay M, Bernasconi E, Böni J.

Abstract

AIMS:

HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.

METHODS AND RESULTS:

Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score.

CONCLUSION:

Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

PMID:
20543702
DOI:
10.1097/HJR.0b013e328336a150
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center